| Title |
Effects of flumazenil in the treatment of benzodiazepine withdrawal – a double-blind pilot study
|
|---|---|
| Published in |
Psychopharmacology, May 1997
|
| DOI | 10.1007/s002130050278 |
| Pubmed ID | |
| Authors |
L. Saxon, P. Hjemdahl, A. J. Hiltunen, S. Borg |
| Abstract |
Flumazenil, a partial benzodiazepine agonist with low intrinsic activity, was tested for potential use in patients experiencing withdrawal symptoms after traditional treatment for benzodiazepine dependency. On two occasions, separated by 1-13 weeks, ten patients treated for benzodiazepine dependency and ten controls received cumulative doses of flumazenil (0.05, 0.10, 0.25, 0.50 and 1.00 mg at 15-min intervals) or placebo, with assessments of withdrawal symptoms and physiological variables after each dose. As expected, there was an overall difference between patients and controls, with patients scoring higher on negative and somatic items and lower on positive psychological items. Flumazenil reduced symptoms thought to be important in withdrawal in patients treated for benzodiazepine dependency. In contrast to the patient group, controls reacted in the opposite direction with increases in negative experience when given flumazenil. Further research may develop flumazenil as a therapeutic option in the treatment of benzodiazepine withdrawal. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 4% |
| Unknown | 22 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 26% |
| Student > Master | 3 | 13% |
| Student > Ph. D. Student | 3 | 13% |
| Student > Doctoral Student | 2 | 9% |
| Other | 1 | 4% |
| Other | 4 | 17% |
| Unknown | 4 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 43% |
| Psychology | 3 | 13% |
| Agricultural and Biological Sciences | 2 | 9% |
| Unspecified | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 9% |
| Unknown | 4 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2023.
All research outputs
#3,335,273
of 25,374,647 outputs
Outputs from Psychopharmacology
#814
of 5,320 outputs
Outputs of similar age
#1,951
of 29,382 outputs
Outputs of similar age from Psychopharmacology
#4
of 20 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,320 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 29,382 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.